

DEC. 14, 2005 10:55AM

GLAXO WELLCOME

NO. 8746 P. 1

# FAX



RECEIVED  
CENTRAL FAX CENTER  
DEC 14 2005  
GlaxoSmithKline

To Attn: OIPE  
Company USPTO  
Fax 571-273-8300  
From Marjorie J. Pfeiffer  
Tel 1-919-483-9038; Facsimile: 1-919-483-7988  
E-mail [marjorie.j.pfeiffer@gsk.com](mailto:marjorie.j.pfeiffer@gsk.com)  
Date December 14, 2005 Pages including cover 5  
Subject Request for Corrected Filing Receipt

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

Re: Application of Rachael Ann ANCLIFF et al.  
U.S. Serial No.: 10/509,162 Filed: June 10, 2005  
Title: *Morpholinyl-urea Derivatives for use of the Treatment of Inflammatory Diseases*  
Attorney Docket No. PG4784USw

Attached:

1. Request for Corrected Filing Receipt with a Certificate of Transmission
2. Copy of Official Filing Receipt (3 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

DEC. 14. 2005 10:55AM GLAXO WELLCOME

NO. 8746 P. 2

Atty. Dkt. No. PG4784USw

RECEIVED  
CENTRAL FAX CENTER

DEC 14 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rachael Ann ANCLIFF et al.

Serial No.: 10/509,162

Filed: June 10, 2005

For: *Morpholinyl-urea Derivatives for use of the  
Treatment of Inflammatory Diseases*

Unit: 1615

Examiner: To be assigned

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is:

incorrectly entered

and/or


omitted.

Error in

1.  Applicant's name 10<sup>th</sup> inventor
2.  Applicant's address
3.  Title
4.  Filing date
5.  Serial Number
6.  Foreign/PCT Application Re:
7.  Other:

Correct data

1. Xiao Qing Lewell
- 2.
3. **Morpholinyl-urea Derivatives for use of the  
Treatment of Inflammatory Diseases**
- 4.
- 5.
- 6.
- 7.

  
James P. Rieck

Registration No.: 39,009

Date: 12-14-05

GlaxoSmithKline  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Phone: 919-483-8022  
Fax: 919-483-7988

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: M/S XXX, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: 12-14-2005

  
MARJORIE J. PFEIFFER

DEC. 14. 2005 10:56AM

GLAXO WELLCOME

NO. 8746 P-1 of 3

COPIED TO THE UK



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

LPT/JR/AMP/Mary

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS.
10/509,162	06/10/2005	1615	✓1104	PG4784USW	✓23	✓3	

23347

GLAXOSMITHKLINE  
 CORPORATE INTELLECTUAL PROPERTY, MAI B475  
 FIVE MOORE DR., PO BOX 13398  
 RESEARCH TRIANGLE PARK, NC 27709-3398

CONFIRMATION NO. 5044

## FILING RECEIPT



\*OC000000017440472\*

Date Mailed: 11/14/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

- ✓ Rachael Ann Ancliff, Hertfordshire, UNITED KINGDOM;
- ✓ Caroline mary Cook, Hertfordshire, UNITED KINGDOM;
- ✓ Colin David Eldred, Hertfordshire, UNITED KINGDOM;
- ✓ Paul Martin Gore, Hertfordshire, UNITED KINGDOM;
- ✓ Lee Andrew Harrison, Hertfordshire, UNITED KINGDOM;
- ✓ Martin Alister Hayes, Hertfordshire, UNITED KINGDOM;
- ✓ Sirion Teanby Hodgson, Hertfordshire, UNITED KINGDOM;
- ✓ Duncan Bruce Judd, Hertfordshire, UNITED KINGDOM;
- ✓ Suzanne Elaine Keeling, Hertfordshire, UNITED KINGDOM;
- ✓ Xiao Qing Lewell, Hertfordshire, UNITED KINGDOM;
- ✓ Sall Mills, Hertfordshire, UNITED KINGDOM;
- ✓ Graeme Michael Robertson, Hertfordshire, UNITED KINGDOM;
- ✓ Stephen Swanson, Hertfordshire, UNITED KINGDOM;
- ✓ Andrew John Walker, Hertfordshire, UNITED KINGDOM;
- ✓ Mark Wilkinson, Hertfordshire, UNITED KINGDOM;

Qing


✓ Power of Attorney: The patent practitioners associated with Customer Number 23347.

## ✓ Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/03335 03/27/2003

## ✓ Foreign Applications

UNITED KINGDOM 0207434.2 03/28/2002  
 UNITED KINGDOM 0301608.6 01/24/2003



Projected Publication Date: 02/16/2006

Non-Publication Request: No

Early Publication Request: No

Title

Novel compounds

Preliminary Class

514

### PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

DEC. 14. 2005 10:56AM

GLAXO WELLCOME

NO. 8746 P<sub>5</sub> 5; of 3

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).